CD274 and breast cancer: formulated a cyclic RGD (cRGD)-modified liposomal delivery system loaded with anti-PD-L1 and PS pheophorbide A and tried to target 4T1 mouse breast cancer cells with low PD-L1 expression by recognizing overexpressed surface αvβ3 integrin.